Secondary endpoint
CAMZYOS significantly improved post-exercise LVOT obstruction vs placebo at Week 301,2
Change in mean post-exercise LVOT peak gradient from baseline to Week 301,2
EXPLORER-HCM: CAMZYOS (mavacamten) demonstrated significant improvements across all analysed secondary endpoints vs placebo at Week 301,2
Secondary endpoint
CAMZYOS significantly improved post-exercise LVOT obstruction vs placebo at Week 301,2
Change in mean post-exercise LVOT peak gradient from baseline to Week 301,2
Adapted from Olivotto I et al. 2020.2
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
relative improvement in post-exercise LVOT
obstruction vs placebo at Week 301,2
Secondary endpoint
CAMZYOS significantly improved peak oxygen consumption (pVO2) vs placebo at Week 301,2
Mean change in pVO2 from baseline to Week 301,2
Treatment difference, 1.4; 95% CI: 0.6 to 2; p<0.0006
Adapted from Olivotto I et al. 2020.2
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
Secondary endpoint
Significantly more patients improved by ≥1 NYHA class with CAMZYOS vs placebo at Week 301,2
Percentage of patients who improved NYHA score by ≥1 class from baseline to Week 301,2
Treatment difference, 34%; 95% CI: 22 to 45; p<0.0001
Adapted from Olivotto I et al. 2020.2
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
as many patients improved by ≥1 NYHA
class vs placebo at Week 301,2
Secondary endpoint
CAMZYOS demonstrated significant improvements in patient-reported symptom burden and physical limitations vs placebo1,2
KCCQ-23 CSS: mean change from baseline to Week 30*1,3
Adapted from Spertus JA et al. 2021.3
*Due to the smaller numbers evaluable for patient-reported outcome endpoints, additional post hoc analyses compared the reasons for missing data.2
Secondary endpoint
CAMZYOS demonstrated significant mean improvements in patient-reported frequency and severity of shortness of breath vs placebo1,2
Adapted from Naidu SS et al. 2021.4
*Due to the smaller numbers evaluable for patient-reported outcome endpoints, additional post hoc analyses compared the reasons for missing data.2
See the safety profile
Please refer to the CAMZYOS Summary of Product Characteristics for further information on dosing, initiation and safety.
CI, confidence interval; HCMSQ-SoB, Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness-of-Breath; KCCQ-23 CSS, Kansas City Cardiomyopathy Questionnaire-23 Clinical Summary Score; LS, least square; LVOT, left ventricular outflow tract; NYHA, New York Heart Association; pVO2, peak oxygen consumption; SD, standard deviation; SoC, standard of care.